Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier

INTRODUCTION: Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline could pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Dawn C., Lukic, Ana S., Andrews, Randolph D., Wernick, Miles N., Strother, Stephen C., Schmidt, Mark E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270637/
https://www.ncbi.nlm.nih.gov/pubmed/35846158
http://dx.doi.org/10.1002/trc2.12325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270637/
https://www.ncbi.nlm.nih.gov/pubmed/35846158
http://dx.doi.org/10.1002/trc2.12325

Ejemplares similares